Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 15, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 480,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 15, 2012.
- Price Range: Highest price paid was 1,439.5 pence per share; lowest price paid was 1,423 pence per share.
- Treasury Holdings (Settled): 505,810,427 shares (9.29% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,590,427 shares (10.28% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,939,282,684 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 480,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.28% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (505,810,427 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (4,939,282,684 shares in issue) for disclosure threshold assessments.
- Check the status of the 1,780,000 shares purchased but not yet settled to determine final Treasury holdings.
- Review the price paid (1,423 to 1,439.5 pence) against the market price on October 15, 2012.